Business Description
Benitec Biopharma Inc
NAICS : 325412
SIC : 2834
ISIN : AU000000BLT8
Description
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 321.52 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 5/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -67.8 | |||||
| 3-Year EBITDA Growth Rate | 53.2 | |||||
| 3-Year EPS without NRI Growth Rate | 53.4 | |||||
| 3-Year FCF Growth Rate | 53.2 | |||||
| 3-Year Book Growth Rate | -90.8 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | -33.33 | |||||
| 12-1 Month Momentum % | -71.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 15.01 | |||||
| Quick Ratio | 15.01 | |||||
| Cash Ratio | 14.9 | |||||
| Days Payable | 526768 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -193.4 | |||||
| Shareholder Yield % | -28.5 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -64.89 | |||||
| ROA % | -56.55 | |||||
| ROIC % | -1690.07 | |||||
| ROC (Joel Greenblatt) % | -4796.61 | |||||
| ROCE % | -69.27 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 180.19 | |||||
| PB Ratio | 2.71 | |||||
| EV-to-EBIT | -7.04 | |||||
| EV-to-EBITDA | -7.14 | |||||
| EV-to-Revenue | 2094.01 | |||||
| EV-to-FCF | -8.15 | |||||
| Earnings Yield (Greenblatt) % | -14.21 | |||||
| FCF Yield % | -8.59 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Benitec Biopharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | 0 | ||
| Beta | 0 | ||
| Volatility % | 96.31 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | -71.43 | ||
| 52-Week Range (€) | 0.01 - 0.09 | ||
| Shares Outstanding (Mil) | 321.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Benitec Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Benitec Biopharma Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Benitec Biopharma Inc Frequently Asked Questions
What is Benitec Biopharma Inc(FRA:BJ9)'s stock price today?
The current price of FRA:BJ9 is €0.01. The 52 week high of FRA:BJ9 is €0.09 and 52 week low is €0.01.
When is next earnings date of Benitec Biopharma Inc(FRA:BJ9)?
The next earnings date of Benitec Biopharma Inc(FRA:BJ9) is 2025-02-13 Est..
Does Benitec Biopharma Inc(FRA:BJ9) pay dividends? If so, how much?
Benitec Biopharma Inc(FRA:BJ9) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers